How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

804 results for

Priapism

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

721. Trazodone for Sleep Disturbance in Early Alcohol Recovery

of proerectile agents, herbal medications or sleep medication for the study period. The presence of contraindications to the study medications, including pregnancy/lactation, ischemic heart disease, cardiac arrhythmias, priapism or hypotension. Presence of comorbid medical conditions associated with sleep disturbance including obstructive sleep apnea, poorly controlled diabetes mellitus or emphysema. Evidence of neuropsychological dysfunction. Probation/parole requirements that might interfere

2001 Clinical Trials

722. ABC of Urology. Urological emergencies in general practice. Full Text available with Trip Pro

):112; author reply 112-3 8688727 Colic therapy Emergencies Family Practice Humans Kidney Diseases therapy Male Paraphimosis therapy Priapism therapy Spermatic Cord Torsion therapy Urinary Retention therapy 0 1996 3 30 1996 3 30 0 1 1996 3 30 0 0 ppublish 8608297 PMC2350694

1996 BMJ : British Medical Journal

723. Perioperative Management in Children with Sickle Cell Disease Undergoing Laparoscopic Surgery Full Text available with Trip Pro

. Twelve patients received packed red blood cell transfusions prior to surgery. The median operative time was 150 minutes, and the median hospitalization was 3 days. Four patients suffered postoperative complications (2 with acute chest syndrome, 1 with recurrent abdominal pain, and 1 with priapism). The patient with abdominal pain was found to have a retained stone in the common bile duct, which was retrieved via endoscopic retrograde cholangiopancreatography and sphincterotomy. All complications

2002 JSLS : Journal of the Society of Laparoendoscopic Surgeons

724. Prolonged erections produced by dihydrocodeine and sildenafil Full Text available with Trip Pro

Codeine AIM IM Adult Analgesics, Opioid adverse effects Codeine adverse effects analogs & derivatives Drug Interactions Humans Male Middle Aged Piperazines adverse effects Priapism chemically induced Purines Sildenafil Citrate Sulfones Vasodilator Agents adverse effects 2002 6 29 10 0 2002 7 19 10 1 2002 6 29 10 0 ppublish 12089093 PMC116609 Urology. 2000 Jun 1;55(6):950 10840123 Blood. 2000 Mar 1;95(5):1878-9 10744389 Am J Psychiatry. 1980 Aug;137(8):909-15 6774622

2002 BMJ : British Medical Journal

725. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. (Abstract)

effects reported at a rate of >2% were headache, flushing, dyspepsia, nasal congestion, urinary tract infection, abnormal vision, diarrhea, dizziness, and rash. No cases of priapism were reported. The use of sildenafil is contraindicated in men who are taking organic nitrates, because of the potential for a precipitous decrease in blood pressure. Postmarketing reports and surveillance have revealed at least 39 deaths with sildenafil use in men having a history of heart disease, men taking nitrate

1999 Clinical therapeutics

726. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature]. (Abstract)

of the 9 patients which in the initial tests had not obtained sufficient erection, therefore bringing about a final 91.4% erections of sufficient characteristics for intercourse to be considered normal. During the year and a half follow-up a total of 2,880 E1-PG self-injections were injected without during this time cases of priapism, systemic reactions, cavernous bodies infections, arteriovenous fistulae, fibrosis of the cavernous bodies, etc, being observed. Two patients showed prolonged erections

1992 Actas urologicas espanolas Controlled trial quality: uncertain

727. Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo. (Abstract)

tumescence in 6, partial rigidity in 16 and complete rigidity in 46. Thus, in 62 of 73 patients (85%) the drug allowed initiation of erection adequate for intercourse. Placebo induced such erection in only 25% of the cases and in 55% there was no response. Tolerance was good and no priapism occurred. Only 4 patients (5%) reported mild pain during injection but erections were never painful, 1 presented with moderate and transient hypotension at the 20 mg. dose and a painless prolonged erection

1993 The Journal of urology Controlled trial quality: uncertain

728. Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. (Abstract)

Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. Prolonged erections, priapism, secondary to pharmacologic stimulation are usually treated by drainage of the corporeal bodies and irrigation with a sympathomimetic. To study the efficacy of oral medical therapy in the treatment of priapism, 75 patients with pharmacologically induced (prostaglandin E1) prolonged erections were randomized to receive terbutaline

1993 Urology Controlled trial quality: uncertain

729. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. (Abstract)

. 001), with a median duration of erection of 56 min. The principal adverse event was transient facial flushing accompanying 40% of 1711 injections. There was no pain after injection and one episode of priapism (0.06%); only seven patients withdrew because of adverse events. Over 88% and 92% of patients were satisfied with the drug and auto-injector, respectively. More than 85% of patients and 77% of partners reported an improved quality of life.The combination of VIP and PM at the dose used

1999 BJU international Controlled trial quality: uncertain

730. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial. (Abstract)

Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial. The unusual side effect of priapism associated with the antidepressant trazodone has led researchers to evaluate its use for the treatment of erectile dysfunction. Previous studies have shown nearly 70% efficacy in patients. Unfortunately, these studies have been anecdotal, retrospective or of combination therapy with yohimbine. A placebo controlled, fixed dose, double-blind crossover

1999 The Journal of urology Controlled trial quality: predicted high

731. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. (Abstract)

injections (33.9%). There was no pain post injection and two episodes of priapism (0.05%). Only nine patients withdrew because of adverse events. Over 85% and 95% of patients were satisfied with the drug and auto-injector, respectively. Over 81% of patients and 76% of partners reported an improved quality of life.

1999 International journal of impotence research

732. [Effectiveness of and tolerance to intracavernous injection of moxisylyte in patients with erectile dysfunction: effect/dose relationship versus placebo]. (Abstract)

and no case of priapism was observed. One patient (neurological patient) experienced two prolonged erections after the dose of 20 mg and another patient (psychological patient) reported 2 headaches after the dose of 30 mg. No pain was experienced on injection. Moxisylyte is very well tolerated and is able to induce an erectile response from the dose of 10 mg. This dose appears to be sufficient in patients with central neurological erectile dysfunction; a dose of 20 mg tends to improve the quality

1995 Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie Controlled trial quality: uncertain

733. Preliminary results of a comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction. (Abstract)

and decreasing the risk of priapism), prostaglandin E1 still remains the agent of choice for intracavernous use.

1995 The Journal of urology Controlled trial quality: uncertain

734. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. (Abstract)

ratings ranged from 79 to 87, depending on dose, where 0 = severe discomfort and 100 = comfortable; ease of administration scores were above 90 for each dose, where 0 = difficult and 100 = easy. There were no episodes of priapism in this study.Short-term treatment with transurethral alprostadil produced erections resulting in sexual intercourse in most patients with chronic erectile dysfunction. This therapy may be a useful treatment option for patients with erectile dysfunction.

1996 Urology Controlled trial quality: uncertain

735. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. (Abstract)

), flushing (10% sildenafil, 1% placebo), and dyspepsia (7% sildenafil, 2% placebo) and they were predominantly transient and mild or moderate in nature. These adverse events reflect the pharmacology of sildenafil as a phosphodiesterase type 5 inhibitor. No cases of priapism were reported. The rate of discontinuation due to adverse events (all causes) was comparable for patients treated with sildenafil (2.5%) and placebo (2.3%). In open-label extension studies, 90% of patients completed long-term

1998 International journal of impotence research Controlled trial quality: uncertain

736. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. (Abstract)

, was reported by 7% of patients in the clinic. Most patients (83%) graded transurethral alprostadil as causing minimal or no discomfort in the clinic. No patient reported priapism or developed penile fibrosis.Alprostadil delivered transurethrally by this system was well tolerated and effective in treating erectile dysfunction.

1998 British journal of urology Controlled trial quality: uncertain

737. Optimizing the therapeutic approach of transurethral alprostadil. (Abstract)

patients reported penile pain while treated with 500 microg than with 250 microg (P < 0.05) during the first 4 weeks. However, the penile pain was severe in very few men and it was a minor problem. Hypotensive symptoms were reported six times, independently of dose level. The administration of MUSE was generally rated as comfortable. No patients reported urethral stricture, penile fibrosis, or priapism either in the clinic or at home.Recommending 500 microg as a starting dose increased the percentage

2000 BJU international Controlled trial quality: uncertain

738. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients. (Abstract)

, circumference and hardness after the administration of the experimental and control drugs were assessed and compared statistically.(1) There was no significant difference between the changes in penile length and circumference in the two occasions; (2) In 25 SNP and 28 control cases, the hardness of the penis was scored above 100 as evaluated by the Virag method (P > 0.05); (3) The duration of erection in the controls was longer than that in the SNP, but there were three priapism in the controls (...) and not a single one in the SNP; (4) there was no apparent change in the heart rate and blood pressure in both occasions; other side effects were minimal except slight local pain in a few controls.SNP facilitates relaxation of the penile smooth muscle and penile erection without significant side effects. SNP may be used in ED patients that experience pain and priapism with papaverine/phentolamine.

2000 Asian journal of andrology Controlled trial quality: uncertain

739. Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence. (Abstract)

in 24 patients (82.8 per cent) and no erection occurred after injection of saline. Of the patients 12 (41.4 per cent) experienced technical difficulties with the injection. Ecchymosis of the penis at the site of injection was common and 1 patient experienced priapism that resolved spontaneously. No other side effects occurred. Intracavernous self-injection with phentolamine and papaverine appears to be a safe and effective treatment of impotence but long-term effects must be determined.

1987 The Journal of urology Controlled trial quality: uncertain

740. Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients. (Abstract)

was tolerable and transient, and the positive erectile response was not attended by priapism even in patients who formerly had priapism with papaverine hydrochloride. However, presently with prostaglandin E1 the relatively higher cost and shorter expiration period would probably limit its diagnostic and therapeutic use in Egypt, and probably in other developing countries.

1992 The Journal of urology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>